Register for our free email digests:
Regeneron Pharmaceuticals, Inc.
http://www.regeneron.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Regeneron Pharmaceuticals, Inc.
Servier and MiNA Target Neurodegenerative Disease With Novel RNA Therapy
Already partnering with AZ and Boehringer Ingelheim in liver targets, the UK biotech sees potential to hit ‘undruggable’ CNS targets as well.
Lilly COVID-19 Antibody Has Role As Stopgap When Too Late To Vaccinate
The company will seek emergency use authorization to prevent outbreaks in nursing homes. Regeneron is also positioning its antibody cocktail to prevent infections.
Humanigen Takes Aim At IL-6 Inhibitors With CRS Drug Lenzilumab
Roche's Actemra is a major player in this space, but Humanigen is looking to take it on directly.
Breakthroughs, Orphans Hit High Notes As US FDA’s 2020 Novel Approvals Play A Familiar Tune
Influence of expedited review pathways and regulatory incentives is on display in 2020’s novel approvals, which have a composition reassuringly consistent with recent years.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
- Gene Therapy, Cell Therapy
-
Large Molecule
- Antibodies
- Other Names / Subsidiaries
-
- Regeneron Genetics Center LLC (RGC)